^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BR-DIM (oral microencapsulated diindolylmethane)

    Associations

    News

    Trials
    Company:
    BioResponse
    Drug class:
    Estrogen receptor modulator
    Related drugs:
    Associations

    News

    Trials
    3ms
    Employing cancer driver genes for the identification of immunological features in two esophageal cancer subtypes to facilitate immunotherapy. (PubMed, Immunopharmacol Immunotoxicol)
    Additionally, potential small-molecule drugs targeting DEGs in ESCA were investigated, such as 3,3'-diindolylmethane, SJ-172550, aminoglutethimide, nitrazepam, actarit, and epigallocatechin. The results of qRT-PCR showed that RUNX1, NONO, and TSC2 were not only significantly associated with the survival of esophageal squamous cell carcinoma (ESCC) but also significantly overexpressed in the ESCC cell lines (KYSE150 and KYSE450). This study is valuable for elucidating CDG functions in ESCA and for biomarker identification.
    Journal • IO biomarker
    |
    RUNX1 (RUNX Family Transcription Factor 1) • TSC2 (TSC complex subunit 2)
    |
    BR-DIM (oral microencapsulated diindolylmethane)
    3years
    Dietary Diindolylmethane Enhances the Therapeutic Effect of Centchroman in Breast Cancer by Inhibiting Neoangiogenesis. (PubMed, Nutr Cancer)
    Interestingly, the DIM and CC combination also suppressed the lung metastasis of the highly metastatic 4T1 tumors through the downregulation of FAK/MMP9/2 signaling and reversal of epithelial-to-mesenchymal transition (EMT). Overall, these findings suggest that DIM-based nutraceuticals and functional foods can be developed as adjuvant therapy for treating TNBC.
    Journal
    |
    KDR (Kinase insert domain receptor) • MMP9 (Matrix metallopeptidase 9)
    |
    VEGFA expression
    |
    BR-DIM (oral microencapsulated diindolylmethane)
    over5years
    3,3-Diindolylmethane (DIM): A nutritional intervention and its impact on breast density in healthy BRCA carriers. A prospective clinical trial. (PubMed, Carcinogenesis)
    In conclusion, one year's supplementation with DIM 100 mgX1/d in BRCA carriers was associated with a significant decline in FGT amount on MRI. Larger randomized studies are warranted to corroborate these findings.
    Clinical • Journal • BRCA Biomarker
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    BR-DIM (oral microencapsulated diindolylmethane)
    over5years
    [VIRTUAL] 3,3'-Diindolylmethane (DIM): A nutritional intervention and its impact on breast density in healthy BRCA carriers compared to non-treated carriers—A prospective clinical trial. (ASCO 2020)
    One year’s supplementation with DIM 100 mgX1/d in BRCA carriers was associated with a significant decline in FGT amount on MRI. Larger randomized studies are warranted to corroborate these findings. Research Funding: Israel Cancer Association
    Clinical • BRCA Biomarker
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    BR-DIM (oral microencapsulated diindolylmethane)